
Elizabeth A. Stewart, MD - Advances in Medical Options for Uterine Fibroids and Endometriosis: Clinical Highlights From Montreal
07/15/19 • 30 min
Previous Episode

Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
Next Episode

David F. McDermott, MD - Redefining the Management of Advanced RCC: An Expert Tumor Board on Rational Selection, Sequencing, and Combination of Targeted Agents and Immunotherapy
Go online to PeerView.com/FPP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, recorded from a live event at the 2019 American Society of Clinical Oncology Annual Meeting, a panel of kidney cancer experts offers case-centric discussion of key evidence that supports clinical decision-making through multiple lines of therapy in advanced RCC, as well as practical instruction on how to effectively and safely integrate novel targeted and immunotherapeutic strategies in an increasingly complex RCC treatment landscape. Upon completion of this activity, participants should be better able to: Summarize the latest evidence and ongoing investigations with novel approaches, including new multitargeted tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, and combination therapies, in advanced renal cell carcinoma (RCC), Select optimal frontline treatment options among TKIs and combination approaches (dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors) for individual patients with advanced RCC based on relevant patient- and disease-related characteristics, including in the context of clinical trial enrollment, Recommend targeted agents and immune checkpoint inhibitors optimally to patients with pretreated advanced RCC through multiple lines of therapy, with considerations of prior treatment history and patient comorbidities, Employ effective strategies to prevent and/or manage treatment-related complications with multitargeted TKIs and immune checkpoint inhibitor therapy in patients with RCC.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/peerview-kidney-and-genitourinary-diseases-cmecnecpe-audio-podcast-25531/elizabeth-a-stewart-md-advances-in-medical-options-for-uterine-fibroid-4346748"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to elizabeth a. stewart, md - advances in medical options for uterine fibroids and endometriosis: clinical highlights from montreal on goodpods" style="width: 225px" /> </a>
Copy